Price Alert

CASI Pharmaceuticals Inc. (CASI)

NASDAQ: CASI · Real-Time Price · USD

2.28

-0.05 (-2.15%)

At close: Sep 04, 2025, 3:59 PM

2.28

0.01%

Pre-market: Sep 05, 2025, 08:41 AM EDT

-2.15% (1D)

Bid	2.08
Market Cap	35.32M
Revenue (ttm)	31.56M
Net Income (ttm)	-46.89M
EPS (ttm)	-2.89
PE Ratio (ttm)	-0.79
Forward PE	-1.43
Analyst	Buy

Ask	2.6
Volume	91,468
Avg. Volume (20D)	1,330,419
Open	2.27
Previous Close	2.33
Day's Range	2.18 - 2.37
52-Week Range	1.09 - 7.67
Beta	0.61

About CASI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CASI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CASI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

CASI Pharmaceuticals has released their quartely earnings on Aug 29, 2025:

Revenue of $4.17M misses estimates by $2.1M, with 4.93% YoY growth.

EPS of -0.86 misses estimates by -0.39, with -65.38% YoY decline.

Next Earnings Release

CASI Pharmaceuticals Inc. is scheduled to release its earnings on Sep 9, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+51.16%

CASI Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription

5 months ago

+0.95%

CASI Pharmaceuticals shares are trading higher after the company received a $20 million proposal from CEO Dr. Wei-Wu He to acquire its business operations in China.

News

1 day ago · accessnewswire.com

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for pati...

2 days ago · accessnewswire.com

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations - Ope...

6 days ago · accessnewswire.com

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies fo...

1 week ago · accessnewswire.com

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients wit...

1 month ago · accessnewswire.com

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is ...

1 month ago · accessnewswire.com

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record o...